Egypt’s Type II Diabetes Mellitus drug market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Type 2 diabetes (T2D) is a chronic disease that affects the body’s blood sugar level. Elevated blood sugar level (hyperglycemia) causes detrimental effects on the heart, kidneys, eyes, blood vessels, and nerves.
Currently, the prevalence of Type 2 diabetes in Egypt is around 15.6% of all adults aged 20 to 79. Egypt and Saudi Arabia have the highest diabetic population, with 53.3% and 28.2% market share in 2018 in middle east Asia. This rising trend in the prevalence of chronic disease in the population of Egypt has increased the demand for new and efficient treatment in the market.
Egypt’s rising geriatric population poses the risk of rising disease burden of non-communicable diseases in Egypt especially diabetes and heart-related disorders. The rapid societal transition to a more urbanized lifestyle with little exercise and westernized diets has caused a huge increase in obesity, which in turn has seen huge increases in diabetes mellitus rates. Diabetes prevalence in Egypt is high compared to global levels and this is expected to keep the demand of diabetes treatment high and boost the sector’s growth in the market in the forecast period.
As more and more people are rapidly becoming aware of these common health hazards, they are seeking treatments, and this will lead to market growth in the forecast period.